Revelation Biosciences Lead Product Tested For SARS-CoV-2 Treatment

Revelation Biosciences announced that it has observed a serious decrease in the viral load with the use of its lead product candidate, REVTx99, in three independent in vitro cell-based assays for the treatment of SARS-CoV-2 infections. In connection with the purchase of Petra Acquisition, Inc., the company has been trading on the market with “REV” name since January 11. REVTx99 is a novel drug candidate that activates the toll-like receptor 4 (TLR4), which is a key component of the host’s response to infection.

Revelation Biosciences

Revelation Biosciences’ lead product candidate was tested for its ability to prevent infection with SARS-CoV-2 Delta by inactivating the TLR4 and ACEII receptors. A human bronchial/tracheal cell was treated with 250 nanograms per mL of REVTx99 for one hour before infection. The viral load was then decreased by more than 50%. Through in vitro and in vivo studies, the company is developing a strategy to identify a dose range that can maximize the anti-viral effects of REVTx99 against different strains of SARS-CoV-2.